Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Head and Neck NeoplasmProstatic NeoplasmPancreatic Neoplasm

Interventions

DRUG

PF00562271

125 mg twice daily \[BID\] with food, tablet

DRUG

PF00562271

125 mg BID with food, tablet

DRUG

PF00562271

125 mg BID with food, tablet

DRUG

PF00562271

125 mg BID with food, tablet

Trial Locations (4)

Pfizer Investigational Site, East Melbourne

Pfizer Investigational Site, Nashville

Pfizer Investigational Site, Aurora

Pfizer Investigational Site, Toronto

All Listed Sponsors

lead

Verastem, Inc.

INDUSTRY

NCT00666926 - Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | Biotech Hunter | Biotech Hunter